Year Founded
1999
Ownership
Public
Employees
~50
Stage
Phase 3
Modalities
Autologous cell therapyGene therapy

Kolon TissueGene General Information

Completed patient dosing in two Phase 3 clinical trials for TG-C in knee osteoarthritis involving 1,066 patients. Two-year follow-up period ongoing. Previous Phase 2 trial demonstrated two-year improvement in pain and function.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Rockville, Maryland
United States

Drug Pipeline

TG-C
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Kolon TissueGene's pipeline data

Book a demo

Key Partnerships

Lonza

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Kolon TissueGene Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Kolon TissueGene's complete valuation and funding history, request access »

Kolon TissueGene Investors

Kolon Corporation
Investor Type: Venture Capital
Holding: Minority
Kolon Life Science
Investor Type: Venture Capital
Holding: Minority
Other private investors via parent group structure.
Investor Type: Venture Capital
Holding: Minority